WO2004034977A3 - Orally administered peptides synergize statin activity - Google Patents

Orally administered peptides synergize statin activity Download PDF

Info

Publication number
WO2004034977A3
WO2004034977A3 PCT/US2003/032442 US0332442W WO2004034977A3 WO 2004034977 A3 WO2004034977 A3 WO 2004034977A3 US 0332442 W US0332442 W US 0332442W WO 2004034977 A3 WO2004034977 A3 WO 2004034977A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
orally administered
activity
administered peptides
station
Prior art date
Application number
PCT/US2003/032442
Other languages
French (fr)
Other versions
WO2004034977A2 (en
Inventor
Alan M Fogelman
Gattadahalli M Anantharamaiah
Mohamad Navab
Original Assignee
Univ California
Alan M Fogelman
Gattadahalli M Anantharamaiah
Mohamad Navab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/273,386 external-priority patent/US7166578B2/en
Application filed by Univ California, Alan M Fogelman, Gattadahalli M Anantharamaiah, Mohamad Navab filed Critical Univ California
Priority to CN2003801063671A priority Critical patent/CN1744909B/en
Priority to AU2003284129A priority patent/AU2003284129B2/en
Priority to JP2005501402A priority patent/JP2006508179A/en
Priority to EP03776360A priority patent/EP1562624A4/en
Priority to CA002501943A priority patent/CA2501943A1/en
Publication of WO2004034977A2 publication Critical patent/WO2004034977A2/en
Publication of WO2004034977A3 publication Critical patent/WO2004034977A3/en
Priority to HK06109556.1A priority patent/HK1089090A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high-density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the station permitting the station to be used at significantly lower dosages and/or cause the stations to be significantly more anti-inflammatory at any given dose.
PCT/US2003/032442 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity WO2004034977A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2003801063671A CN1744909B (en) 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity
AU2003284129A AU2003284129B2 (en) 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity
JP2005501402A JP2006508179A (en) 2002-10-16 2003-10-14 Synergistic action of orally administered peptide-statin
EP03776360A EP1562624A4 (en) 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity
CA002501943A CA2501943A1 (en) 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity
HK06109556.1A HK1089090A1 (en) 2002-10-16 2006-08-28 Orally administered peptides synergize statin activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/273,386 2002-10-16
US10/273,386 US7166578B2 (en) 2000-08-24 2002-10-16 Orally administered peptides synergize statin activity
US10/423,830 2003-04-25
US10/423,830 US7199102B2 (en) 2000-08-24 2003-04-25 Orally administered peptides synergize statin activity

Publications (2)

Publication Number Publication Date
WO2004034977A2 WO2004034977A2 (en) 2004-04-29
WO2004034977A3 true WO2004034977A3 (en) 2004-11-25

Family

ID=32109821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032442 WO2004034977A2 (en) 2002-10-16 2003-10-14 Orally administered peptides synergize statin activity

Country Status (5)

Country Link
US (7) US7199102B2 (en)
EP (1) EP1562624A4 (en)
JP (1) JP2006508179A (en)
CA (1) CA2501943A1 (en)
WO (1) WO2004034977A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1599173B1 (en) * 2002-11-13 2017-02-22 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
CA2577026A1 (en) * 2004-08-11 2006-02-23 The Regents Of The University Of California Orally administered small peptides synergize statin activity
JP2008513479A (en) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア G-type peptides and other agents for ameliorating atherosclerosis and other pathologies
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
CA2595067A1 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ZA200807389B (en) * 2006-03-24 2010-03-31 Unilever Plc Healthy food product
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2121746B1 (en) 2006-12-13 2011-11-16 The Regents of the University of California Potent and selective mediators of cholesterol efflux
CA2692698A1 (en) * 2007-07-09 2009-01-15 Novartis Ag Preserving secondary peptide structure
JP2010537638A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US20110166227A1 (en) * 2008-08-25 2011-07-07 Brandeis University Balanced myristate- and laurate-containing edible oil
US8617634B2 (en) * 2008-08-25 2013-12-31 Brandeis University Sn-2 myristate-containing edible oil
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
US8114461B2 (en) * 2008-08-25 2012-02-14 Brandeis University Balanced sn-2 myristate-containing edible oil
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
EP3466969A1 (en) 2011-02-07 2019-04-10 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and use thereof
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
WO2013152026A1 (en) * 2012-04-02 2013-10-10 Academia Sinica Use of apolipoprotein a-1 for promoting bone formation
CA2880643A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP2996706B1 (en) 2013-03-14 2019-07-31 UAB Research Foundation Apolipoprotein mimetics and uses thereof
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
JP2017515893A (en) 2014-05-02 2017-06-15 セレニス セラピューティクス ホールディング エスアー HDL treatment marker
JP7081923B2 (en) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol
CN109073590B (en) * 2016-03-30 2021-10-29 池田食研株式会社 Method and kit for amino acid quantification
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
JP7190685B2 (en) * 2017-09-28 2022-12-16 池田食研株式会社 Amino acid quantification method and amino acid quantification kit
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036927A1 (en) * 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
US5733879A (en) * 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030045460A1 (en) * 2000-08-24 2003-03-06 Fogelman Alan M. Orally administered peptides to ameliorate atherosclerosis

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US478593A (en) * 1892-07-12 Window-frame
US541481A (en) * 1895-06-25 Nail-assorting machine
US269755A (en) * 1882-12-26 Weiss
US541494A (en) * 1895-06-25 Wrench
US541482A (en) * 1895-06-25 grove
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
HU185263B (en) * 1981-06-12 1984-12-28 Richter Gedeon Vegyeszet Process for producing peptides effective on the immuncontroll analogous with the tp5
CH661438A5 (en) * 1984-04-09 1987-07-31 Seuref Ag Pharmaceutical compositions acting antianossica and metabolic brain.
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
NZ229004A (en) 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
US5480869A (en) 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
DE4101895C1 (en) 1991-01-23 1991-12-05 Forschungszentrum Juelich Gmbh, 5170 Juelich, De
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
AU672028B2 (en) 1992-08-14 1996-09-19 Shino-Test Corporation Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
EP0945504A3 (en) 1992-12-11 1999-12-08 The University Of Florida Materials and method for control of pests
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
JP3503178B2 (en) 1994-04-07 2004-03-02 松下電器産業株式会社 Gas shut-off device
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1995031474A1 (en) 1994-05-12 1995-11-23 Balazs Sarkadi Compounds for reversing drug resistance
US5595973A (en) 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
FR2735131B1 (en) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S CONJUGATES OF MSH WITH A FATTY ACID, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS
WO1997009048A1 (en) 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
ATE530180T1 (en) 1997-04-02 2011-11-15 Brigham & Womens Hospital METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
WO1998046625A1 (en) 1997-04-11 1998-10-22 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
EP0873687B2 (en) 1997-04-24 2006-04-26 Chemoxal Sa Disinfecting and fungicidal composition based on peracetic acid and an amine oxide
IN185761B (en) 1997-05-13 2001-04-28 Council Scient Ind Res
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
CA2301634A1 (en) 1997-07-15 1999-01-28 Pradeep Ghosh Determining alcohol intake using sialic acid/apo j
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6191151B1 (en) * 1997-11-12 2001-02-20 Howard M. Zik Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
US20030077641A1 (en) 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US6303619B1 (en) 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
AU3356899A (en) 1998-03-17 1999-10-11 Uab Research Foundation, The Synthetic peptides that enhance ldl uptake
US6846636B1 (en) 1998-05-15 2005-01-25 American National Red Cross Methods and compositions for HDL holoparticle uptake receptor
US6019739A (en) * 1998-06-18 2000-02-01 Baxter International Inc. Minimally invasive valve annulus sizer
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6228989B1 (en) 1998-11-13 2001-05-08 The Regents Of The University Of California Peptide substrates phosphorylated by P21-activated protein kinase
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
GB9911689D0 (en) * 1999-05-19 1999-07-21 Medical Res Council Refolding method
US6727063B1 (en) 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes
JP2003513622A (en) 1999-11-02 2003-04-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 19 human secreted proteins
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US6596544B1 (en) 2000-03-31 2003-07-22 The Regents Of The University Of California Functional assay of high-density lipoprotein
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US20020068729A1 (en) 2000-07-13 2002-06-06 Alteon, Inc. Method for treating fibrotic diseases or other indications IC
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
JP2002226457A (en) 2001-02-02 2002-08-14 Ajinomoto Co Inc New cystine derivative and inflammation factor activation inhibitor
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
JP4676676B2 (en) 2001-04-19 2011-04-27 バーテックス ファーマシューティカルズ インコーポレイテッド Heterocyclic dicarbamides as caspase inhibitors
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US20030125260A1 (en) 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity
US7308303B2 (en) 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2005519494A (en) 2002-02-28 2005-06-30 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ Method for controlling the mode of an electronic application
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20140058649A (en) 2002-07-19 2014-05-14 애브비 바이오테크놀로지 리미티드 TREATMENT OF TNFα RELATED DISORDERS
DE10234192B4 (en) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
AU2003291206A1 (en) 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
WO2004069206A2 (en) 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
US20050070996A1 (en) 2003-04-08 2005-03-31 Dinh Thomas Q. Drug-eluting stent for controlled drug delivery
US6936961B2 (en) 2003-05-13 2005-08-30 Eastman Kodak Company Cascaded organic electroluminescent device having connecting units with N-type and P-type organic layers
US7291590B2 (en) 2003-06-12 2007-11-06 Queen's University At Kingston Compositions and methods for treating atherosclerosis
US6986691B2 (en) 2003-10-08 2006-01-17 Steams Inc. Foam stabilization for personal flotation device
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
WO2006020040A2 (en) 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof
JP2008513479A (en) 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア G-type peptides and other agents for ameliorating atherosclerosis and other pathologies
CA2595067A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
RU2007148927A (en) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) NEW TYREOMIMETICS CONTAINING PHOSPHIC ACID
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733879A (en) * 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
WO1997036927A1 (en) * 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
US20010005714A1 (en) * 1996-03-29 2001-06-28 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030045460A1 (en) * 2000-08-24 2003-03-06 Fogelman Alan M. Orally administered peptides to ameliorate atherosclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1562624A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use

Also Published As

Publication number Publication date
US8404635B2 (en) 2013-03-26
AU2003284129A1 (en) 2004-05-04
US20080096814A1 (en) 2008-04-24
EP1562624A4 (en) 2009-07-29
WO2004034977A2 (en) 2004-04-29
US7820784B2 (en) 2010-10-26
US20080096816A1 (en) 2008-04-24
US20040266671A1 (en) 2004-12-30
US7531514B2 (en) 2009-05-12
CA2501943A1 (en) 2004-04-29
US20070254839A1 (en) 2007-11-01
US7807640B2 (en) 2010-10-05
US20120035095A1 (en) 2012-02-09
JP2006508179A (en) 2006-03-09
US20080096815A1 (en) 2008-04-24
US7199102B2 (en) 2007-04-03
US20080045459A1 (en) 2008-02-21
EP1562624A2 (en) 2005-08-17
US7994132B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
WO2004034977A3 (en) Orally administered peptides synergize statin activity
WO2005016280A3 (en) Orally administered small peptides synergize statin activity
WO2006020652A3 (en) Orally administered small peptides synergize statin activity
HK1089090A1 (en) Orally administered peptides synergize statin activity
AU2003286461A8 (en) Navigation and promotion distribution system
MXPA01006803A (en) Taste-masked pharmaceutical particles.
DK1318828T3 (en) Orally administered peptides to improve atherosclerosis
AU2003230303A1 (en) Magnetically levitated transportation system and method
DK1173205T3 (en) Oral formulation for ileum administration, comprising a compound for inhibiting the ileum bile acid transport
EP1539129A4 (en) Dosage forms and related therapies
IL166286A0 (en) Multicomponent pharmaceutical dosage form
EP1531859A4 (en) Compositions and methods for transepithelial molecular transport
AU2003304102A1 (en) In orbit space transportation and recovery system
NO20003234D0 (en) Orally administered ribavirin dosage forms in solid form and process for their preparation
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
AU4955200A (en) A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
EP1105145A4 (en) Method and pharmaceutical composition for reducing serum homocysteine concentration
ECSP066417A (en) SMALL PEPTIDES ADMINISTERED BY THE ORAL ROUTE WITH SYNERGIC ACTION ON THE STATINS
ID24930A (en) PHARMACEUTICAL COMPOSITIONS THAT CONTAIN MICRONIZED BUSINESS DRUGS
AU2003262230A1 (en) Preventive and/or therapeutic drugs for itch
ZA200405372B (en) Sedative non-benzodiazepine formulations.
AU1243101A (en) High dose folic acid for the treatment of hyperhomocysteinemia
EP1512402A4 (en) Inhibitors against complex ii of electron transport system
IT1320329B1 (en) INTERACTIVE TRANSPORT SYSTEM FOR THE HANDLING OF PEOPLE IN AN ENVIRONMENT.
WO2005016254A3 (en) Methods and reagents for treating inflammation and fibrosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003284129

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2501943

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005501402

Country of ref document: JP

Ref document number: 613/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003776360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A63671

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003776360

Country of ref document: EP